中央研究院生醫轉譯研究中心 研究助技師
人類治療性抗體核心設施 計畫主持人
Office: 轉譯中心 B301(國家生技研究園區)
Office TEL: (02)7750-5844
Lab TEL: (02)7750-5800 #2301 #2313
E-mail: reminlu@gate.sinica.edu.tw
研究簡介
我的研究興趣在抗體工程和癌症研究兩個領域，包括基礎機制和轉譯醫學的部分。這些研發成果發表19篇論文於國際學術期刊或專書，並獲得13項國內外發明專利。例如我們從噬菌體顯現人類抗體庫成功篩選對抗 c-Met 和抗 VEGFR2 人類抗體，這些新穎抗體在試管內與小鼠動物模式展現對癌症的治療效果，這兩種抗體已授權給生技公司開發癌症抗體新藥。總計12項抗體專利以及2種技術平台授權給生技公司進一步開發人類疾病治療和診斷方法。另一方面，在全球COVID-19 大流行期間，我參與國家防疫計畫，開發兩項重要產品，即COVID-19血清學側流快篩試劑和NP抗原快篩試劑，分別於2020 和2021年獲得台灣食藥署的緊急使用授權(EUA)。除了在學術界工作外，我曾在生技藥廠業擔任兩年的科學家，負責執行抗體藥物開發的臨床前研究專案。目前，我在中研院生醫轉譯研究中心擔任研究助技師，主持全院性核心設施-人類治療性抗體研發平台的運作，服務的對象包括學界與業界。我們在此建立全新一代噬菌體顯現人類抗體庫、人類單一B細胞技術、小鼠融合瘤技術等抗體篩選製備模式。同時建立了抗體親和力成熟、抗體人源化和Epitope鑑定等抗體工程技術。高度特異性和敏感度的抗體可有效加速學術研究和產品開發，這些科技與經驗可能有助於台灣的應用科學和藥物開發。
Lu, R.M et al. Development of therapeutic antibodies for the treatment of diseases. Journal of Biomedical Science 27, 1, 2020 (1,089 citations, Nov 11, 2022 updated)
https://doi.org/10.1186/s12929-019-0592-z
經歷
2021 – now 研究助技師 中央研究院 生醫轉譯研究中心 人類治療性抗體核心設施
2019 – 2021 特殊技術人員兼研發組長 中央研究院 生醫轉譯研究中心 人類治療性抗體核心設施
2015 - 2019 特殊技術人員 中央研究院 細胞與個體生物學研究所
2013 - 2015 研究員 中天生物科技集團 新藥開發中心
2011 - 2013 院聘博士後研究學者 中央研究院 細胞與個體生物學研究所
2002 - 2006 研究助理 (國防役) 中央研究院 生物醫學研究所
學歷
2006 - 2011 博士 國防醫學院 生命科學研究所(中研院細生所)
2000 - 2002 碩士 台灣大學醫學院 病理學研究所
1996 - 2000 學士 慈濟醫學院 醫事技術學系
研究領域
1. 噬菌體顯現人類抗體庫建立
2. 噬菌體顯現人類抗體篩選技術
3. 抗體工程-抗體重組生產與純化
4. 抗體人源化技術
5. 抗原決定位鑑定
6. 蛋白質工程-重組生產與純化
7. 標的配體藥物傳輸系統
著作目錄
1. Ruei-Min Lu, Kang-Hao Liang, Hsiao-Ling Chiang, Fu-Fei Hsu, Hsiu-Ting Lin, Wan-Yu Chen, Feng-Yi Ke, Monika Kumari, Yu-Chi Chou, Mi-Hua Tao, Yi-Ling Lin, Han-Chung Wu. (2023) Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice. Heliyon. 9, e15587 https://doi.org/10.1016/j.heliyon.2023.e15587
2. Monika Kumari*, Ruei-Min Lu*, Mu-Chun Li, Jhih-Liang Huang, Fu-Fei Hsu, Shih-Han Ko, Feng-Yi Ke, Shih-Chieh Su, Kang-Hao Liang, Joyce Pei-Yi Yuan, Hsiao-Ling Chiang, Cheng-Pu Sun, I.-Jung Lee, Wen-Shan Li, Hsing-Pang Hsieh, Mi-Hua Tao & Han-Chung Wu. (2022) A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. Journal of Biomedical Science 29, 68. https://doi.org/10.1186/s12929-022-00852-9 (*Co-First Author)
3. Yu-Chyi Hwang*, Ruei-Min Lu*, Shih-Chieh Su, Pao-Yin Chiang, Shih-Han Ko, Feng-Yi Ke, Kang-Hao Liang, Tzung-Yang Hsieh & Han-Chung Wu. (2022) Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. Journal of Biomedical Science. 29, 1. https://doi.org/10.1186/s12929-021-00784-w (*Co-First Author)
4. Ruei-Min Lu, Shih-Han Ko, Wan-Yu Chen, Yu-Ling Chang, Hsiu-Ting Lin and Han-Chung Wu. (2021) Monoclonal Antibodies against Nucleocapsid Protein of SARS-CoV-2 Variants for Detection of COVID-19. International Journal of Molecular Science. 22, 12412. https://doi.org/10.3390/ijms222212412
5. Kang-Hao Liang; Pao-Yin Chiang; Shih-Han Ko; Yu-Chi Chou; Ruei-Min Lu; Hsiu-Ting Lin; Wan-Yu Chen; Yi-Ling Lin; Mi-Hua Tao; Jia-Tsrong Jan; Han-Chung Wu. (2021) Antibody cocktail effective against variants of SARS-CoV-2. Journal of Biomedical Science. 28, 80 https://doi.org/10.1186/s12929-021-00777-9 PMID: 34814920
6. Su, S.-C.; Yang, T.-J.; Yu, P.-Y.; Liang, K.-H.; Chen, W.-Y.; Yang, C.-W.; Lin, H.-T.; Wang, M.-J.; Lu, R.-M.; Tso, H.-C.; Chung, M.-J.; Hsieh, T.-Y.; Chang, Y.-L.; Lin, S.-C.; Hsu, F.-Y.; Ke, F.-Y.; Wu, Y.-H.; Hwang, Y.-C.; Liu, I. J.; Liang, J.-J.; Liao, C.-C.; Ko, H.-Y.; Sun, C.-P.; Wu, P.-Y.; Jan, J.-T.; Chang, Y.-C.; Lin, Y.-L.; Tao, M.-H.; Hsu, S.-T. D.; Wu, H.-C. (2021) Structure-guided antibody cocktail for prevention and treatment of COVID-19. PLOS Pathogens 17, (10), e1009704. https://doi.org/10.1371/journal.ppat.1009704 PMID: 34673836
7. Ruei-Min Lu., Wu CH, Patil A.V., Wu, H.C. (2020) Chapter 23: Peptide Targeting Methods. Handbook of In Vivo Chemistry in Mice: From Lab to Living System. WILEY-VCH Book, ISBN 9783527344321. (Invited review article) https://doi.org/10.1002/9783527344406.ch16
8. Ruei-Min Lu, Yu-Chyi Hwang, I-Ju Liu, Chi-Chiu Lee, Han-Zen Tsai, Hsin-Jung Li, Han-Chung Wu. (2020) Development of therapeutic antibodies for the treatment of diseases. Journal of Biomedical Science. 27, 1 (Invited review article) https://doi.org/10.1186/s12929-019-0592-z
9. Ruei-Min Lu, Chiu CY, Liu IJ, Chang YL, Liu YJ, Wu HC. (2019) Novel human Ab against vascular endothelial growth factor receptor 2 shows therapeutic potential for leukemia and prostate cancer. Cancer Science. 110, 3773-3787.https://doi.org/10.1111/cas.14208 PMID: 31578782
10. Lo, W.L., Liang, C.H., Chen, L.C., Lee, S.Y., Lo, S.N., Chen, M.W., Ruei-Min Lu, Liu, I.J., Wu, H.C., Chang, C.H. (2020) Imaging, biodistribution and efficacy of radiolabeled SP90 peptide in BT-483 tumor bearing mice. Applied Radiation and Isotopes. 161, 109162. PMID: 332561130
11. Wu, C. H., Liu, I. J., Ruei-Min Lu., Wu, H. C. (2016). Advancement and applications of peptide phage display technology in biomedical science. Journal of biomedical science. 23, 8. (Invited review article) PMID: 26786672
12. Liao, M. Y., Lai, J. K., Kuo, M. Y. P., Ruei-Min Lu, Lin, C. W., Cheng, P. C., Liang, K. H., Wu, H. C. (2015). An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer. Oncotarget 6, 16253-16270. PMID: 26317650
13. De-Kuan Chang, Pi-Chun Li, Ruei-Min Lu, Wann-Neng Jane, Han-Chung Wu (2013) Peptide-Mediated Liposomal Doxorubicin Enhances Drug Delivery Efficiency and Therapeutic Efficacy in Animal Models. PLoS ONE 8, e83239. PMID: 24386166
14. Ruei-Min Lu, Min-Shan Chen, De-Kuan Chang, Chien-Yu Chiu, Wei-Chuan Lin, Shin-Long Yan, Yi-Ping Wang, Yuan-Sung Kuo, Albert Lo, and Han-Chung Wu. (2013) Targeted drug delivery systems mediated by a novel peptide in breast cancer therapy and imaging. PLoS ONE 8, e66128. PMID: 23776619
15. Cheng-Der Wu, Hung-Wen Chou, Yuan-Sung Kuo, Ruei-Min Lu, Yu-Chyi Hwang, Han-Chung Wu, Chin-Tarng Lin. (2012) Nucleolin antisense oligodeoxynucleotides induce apoptosis and may be used as a potential drug for nasopharyngeal carcinoma therapy. Oncology Reports 27, 94-100. PMID: 21956494
16. Ruei-Min Lu, Yu-Ling Chang, Min-Shan Chen and Han-Chung Wu. (2011) Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials 32, 3265-3274. PMID: 21306768
17. Tung-Ying Lu＊, Ruei-Min Lu＊, Mei-Ying Liao, John Yu, Chu-Hung Chung, Cheng-Fu Kao, and Han-Chung Wu. (2010) Epithelial Cell Adhesion Molecule regulation is associated with the maintenance of the undifferentiated phenotype of human embryonic stem cells. The Journal of Biological Chemistry, 285, 8719-8732. (*Co-First Author) PMID: 20064925
18. Hung-Hsi Chen, Jan-Growth Chang, Ruei-Min Lu, Tsui-Yi Peng, and Woan-Yuh Tarn. (2008) The RNA binding protein hnRNP Q modulates the utilization of exon 7 in the survival motor neuron 2 (SMN2) gene. Molecular and Cellular Biology, 28, 6929-6938. PMID: 18794368
19. Kai-Ti Lin＊, Ruei-Min Lu＊, and Woan-Yuh Tarn. (2004) The WW domain-containing proteins interact with the early spliceosome and participate in pre-mRNA splicing in vivo. Molecular and Cellular Biology, 24, 9176-9185. (*Co-First Author) PMID: 15456888
獲證專利
1. Han-Chung Wu, Ruei-Min Lu, Wan-Yu Chen, Hsiu-Ting Lin. Broadly Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 and Treatment Methods Using the Same. US provisional application No: 63/424,551, filing date Nov 11, 2022.
2. Han-Chung Wu, Ruei-Min Lu, Chiung-Yi Chiu, I-Ju Liu and Yu-Ling Chang. Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy. Spain Patent, ES2882276T3
3. Han-Chung Wu, Ruei-Min Lu, Chiung-Yi Chiu, I-Ju Liu and Yu-Ling Chang. Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy. Australia Patent, AU2016249991B2
4. Han-Chung Wu, Ruei-Min Lu, Chiung-Yi Chiu, I-Ju Liu and Yu-Ling Chang. Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy. Singapore Patent, WO/2016/168159
5. Han-Chung Wu, Ruei-Min Lu, Chiung-Yi Chiu, I-Ju Liu and Yu-Ling Chang. Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy. Canada Patent, CA2981883C
6. Han-Chung Wu, Ruei-Min Lu, Chiung-Yi Chiu, I-Ju Liu and Yu-Ling Chang. 抗血管新生及び標的がん療法のための抗VEGFR2ヒト抗体. Japan Patent, JP特許6542383B2
7. Han-Chung Wu, Ruei-Min Lu, Chiung-Yi Chiu, I-Ju Liu and Yu-Ling Chang. Anti-vascular endothelial growth factor receptor 2 (VEGFR2) antibody and methods of use thereof for detecting VEGFR2 and for inhibiting tumor growth, tumor angiogenesis and/or inducing cancer cell cytotoxicity. U.S. Patent
8. Han-Chung Wu, Ruei-Min Lu, Chiung-Yi Chiu, I-Ju Liu and Yu-Ling Chang. Anti-VEGFR2 human antibody for anti-angiogenic and targeted cancer therapy. Taiwan Patent, I621629
9. Han-Chung Wu and Ruei-Min Lu. 抗ｃ−ｍｅｔ抗体及びその使用方法. Japan Patent, JP5955322B2
10. Han-Chung Wu and Ruei-Min Lu. Anti-c-met antibody and methods of use thereof. Taiwan Patent, I523867
11. Han-Chung Wu and Ruei-Min Lu. Anti-c-met antibody and methods of use thereof. European Union Patent, EP2611928
12. Han-Chung Wu and Ruei-Min Lu. Anti-c-met antibody and methods of use thereof. U.S. Patent, US9150655
13. Han-Chung Wu and Ruei-Min Lu. Anti-c-met antibody and methods of use thereof. China Patent, CN103415619B
14. Han-Chung Wu, Tung-Ying Lu, Cheng-Fu Kao, John Yu and Ruei-Min Lu, and Mei-Ying Liao. Methods of inducing pluripotency. U.S. Patent, US8709806B2
榮譽事項
2022 國家科學及技術委員會 未來科技獎
2021 中央研究院新聘學術研究獎金
2015 中央研究院2015年優勢研究領域-癌症疫苗與抗體新藥研發
2013 中央研究院細生所 學術論文海報比賽 優勝
2012 中央研究院100年度重要研究成果
2011 第8屆國家新創獎 學生組 第三名
2011 第19屆細胞與分子生物新知研討會 優秀壁報論文獎
2010 第37屆 國軍軍醫學術研討會海報競賽 銅牌獎
2010 國防醫學院生命科學研究所 生醫研討會 博士生壁報論文獎
2003 國際基因體學蛋白質體學幹細胞與生醫科技研討會 傑出壁報論文獎
2003 第18屆生物醫學年會 優秀壁報論文獎
2000 醫事檢驗師國家專技高考及格
1996-1998 慈濟醫學院 慈濟公費獎學金